Program
orevandrodeg
Its studies are mostly in Prostatic Neoplasms, led by Bristol-Myers Squibb.
Furthest: phase 1, since Sep 28, 20232 company-led studies, 1 open or runningNext primary completion: Aug 24, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 21 open or running | phase 1since Sep 28, 2023 | Sep 28, 2023 | Aug 24, 2029phase 1 · NCT06067841 |
- Named in Bristol-Myers Squibb’s own pipeline as
BMS-986460
, phase 1, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 28, 2023First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT06067841 · 140 planned · United States, Canada, France
- Mar 10, 2025Phase 1 study in Healthy VolunteersNCT06877702 · 85 enrolled · United States
Ahead
- Aug 24, 2029Primary completion: phase 1 study in Prostatic NeoplasmsNCT06067841
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06877702Healthy Volunteers · United States | 1 | Completed | Dec 17, 2025 | 85 |
| NCT06067841Prostatic Neoplasms · United States, Canada, France | 1 | Recruiting | Aug 24, 2029 | 140 |
How it is read
Names in the registry
- “BMS-986460”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.